Lecithin-Cholesterol Acyltransferase (LCAT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Lecithin-cholesterol acyltransferase (LCAT) deficiency is an autosomal recessive disorder characterized by notably low high-density lipoprotein (HDL) cholesterol levels. This phenotype is less severe compared to individuals with total LCAT deficiency. The observed distinctions between LCAT deficiency and fisheye disease are attributed to mutations in the LCAT gene. These mutations determine whether the gene encodes variants that fail to esterify HDL cholesterol and apoB-containing lipoproteins (leading to LCAT deficiency) or exclusively affect HDL. Clinical features of this disorder include corneal opacities, splenomegaly, normocytic normochromic anemia, low levels of HDL and α-lipoproteins, and elevated LDL levels. Fisheye disease can also manifest without anemia, splenomegaly, or renal complications. Likely, the accumulation of cholesterol-rich multilamellar particles, known as lipoprotein-X, in the plasma plays a role in the kidney's pathogenesis. Renal manifestations primarily ...